iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
New HCV Drug Approvals - studies
 
 
  U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV- (08/11/17)
 
Revisions to the Epclusa Label Approved/ Coinfection Approval- (08/03/17)
 
European Commission Grants Marketing Authorization for Gilead's Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Genotypes of Chronic Hepatitis C- (07/28/17)
 
Gilead Vosevi FDA PI, Package Insert / Label- (08/06/17)
 
AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks- (08/05/17)
 
FDA - G/P - Trials, Package Insert, MAVYRET approved to treat HCV- (08/05/17)
 
European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)- (07/28/17)
 
Cocrystal Announces Positive Data from the Successful Completion of Phase 1a/1b Trial of the Non-Nucleoside Polymerase Inhibitor CC-31244 for the Treatment of Chronic Hepatitis C Infection- (08/14/17)
 
HCV-DAA 57% Survival Benefit - Effect of paritaprevir/ritonavir/ombitasvir/dasabuvir and ledipasvir/sofosbuvir regimens on survival compared with untreated hepatitis C virus-infected persons: results from ERCHIVES- (08/11/17)
 
New HCV AASLD IDSA Guidelines Update Sept 21 2017: New Treatment-Naive & Treatment-Experienced Guidance / Genotype 1 & Genotype 3 - (09/22/17)
 
EASL:New HCV Drugs at EASL 2017- (05/09/17)
 
HCV Retreatment Studies- (05/22/17)
 
IAS: Glecaprevir/Pibrentasvir Fixed-Dose Combination for 8 or 12 Weeks in Patients Co-Infected With HCV and HIV-1: A Sub-Analysis of the Phase 3 ENDURANCE-1 Study - (07/24/17)
 
IAS: Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1: The EXPEDITION-2 Study - (07/24/17)
 
IAS: Maviret /G-P in HIV+ Coinfected / ART DDIs - (09/12/17) 		 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org